Replies to post #205336 on Biotech Values

[dewophile]

the majority are probably not combos and many are investigator sponsored, but of course that list is not exhaustive either
you can look at it one of 2 ways - tons of competition and if a combo hits it could become a new soc especially if it combines with a unique asset so difficult to invest. the flip side is that BMY's lung CA aspirations are already shot and reflected in the stock price to a large degree and you never know who is going to have the combo or combos that will win the day in the end and BMY is very much in that game along w the 3 other players (AZN has combos in NSCLC as well) so it's premature to write them off if you really think monotherapy in 1L is going to be short lived and hence BMY/lung is undervalued